Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases).
Jacques-Eric GottenbergAurore ChaudierYves AllenbachArsene MekinianZahir AmouraPatrice CacoubDivi CornecEric HachullaPierre QuartierIsabelle MelkiChristophe RichezRaphaèle SerorBenjamin TerrierValérie Devauchelle-PensecJulien HenryMarc GatfosseLaurence BouilletEmeline GaigneuxVincent AndreGildas BaulierAurélie SaunierMarie DesmursAntoine PouletMathieu EteBoris BienvenuMarie-Elise TruchetetMartin MichaudClaire LarrocheAzeddine DellalAmélie LeursSebastien OttavianiHubert NiellyGuillaume VialRoland JaussaudBénedicte RouvièrePierre-Yves JeandelAurelien GuffroyAnne-Sophie KorganowMathieu JouvrayAlain MeyerEmmanuel ChatelusChristelle SordetRenaud FeltenJean SibiliaSamira Litim-Ahmed-YahiaJean-François KleinmannXavier MariettePublished in: RMD open (2022)
These initial results of the TATA registry confirm the diversity of targeted treatments prescribed off-label in refractory autoimmune diseases and their corticosteroid-sparing effect when effective. Tolerance was acceptable in these refractory patients with a long history of treatment with immunosuppressive drugs.